Tiziana Life Sciences Ltd (TLSA) Research

Tiziana Life Sciences Ltd is a biotechnology firm dedicated to the research and advancement of novel molecular therapies for human ailments, particularly within oncology and immunology. Its flagship immunology program features Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody under development for a range of conditions including Crohn's disease, graft versus host disease, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel disease, psoriasis, and rheumatoid arthritis. Additionally, the company is progressing Milciclib (TZLS-201), a small molecule inhibitor that targets multiple cyclin-dependent, tropomycin receptor, and Src family kinases to suppress abnormal cell growth and cancer progression. Another significant asset is anti-Interleukin 6 receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody intended to mitigate IL6-induced inflammation and treat COVID-19 patients. Founded in 1998, Tiziana Life Sciences is based in London, United Kingdom.

Market snapshot

Symbol
TLSA
Price
$1.16
Day change
+7.41%
Market cap
$88.1M
P/E ratio
-4.04x
52-week range
1.04-2.6
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 4 months

Recent news

  • Tiziana Life Sciences to present clinical updates at Jefferies healthcare conference

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) said it will present at the Jefferies Global Healthcare Conference in New York on June 4, 2026. CEO Ivor Elrifi and...

  • FedEx sum-of-the-parts valuation points to upside as freight spin-off approaches, UBS says

    UBS is sticking with a Buy rating on FedEx Corp (NYSE:FDX, XETRA:FDX) and a price target of $445, as the company gets ready to spin off its freight business...

  • Tiziana Life Sciences advances foralumab program with full Phase 2 enrollment and encouraging expanded access data – ICYMI

    Tiziana Life Sciences Ltd (NASDAQ:TLSA) has completed enrollment in its Phase 2 clinical trial evaluating foralumab for secondary progressive multiple sclerosis (SPMS), while also reporting expanded access study data suggesting the investigational therapy may deliver clinically meaningful benefits for patients. Speaking with Proactive, CEO Ivor Elrifi said the placebo-controlled study has fully enrolled 48 participants across several leading US institutions, including Harvard, Yale, Cornell, Johns Hopkins, UMass Buffalo and Thomas Jefferson.

Peer companies

  • Anebulo Pharmaceuticals, Inc. (ANEB)
  • Coya Therapeutics, Inc. (COYA)
  • Estrella Immunopharma, Inc. (ESLA)
  • eXoZymes, Inc. (EXOZ)
  • Immix Biopharma, Inc. (IMMX)
  • MacroGenics, Inc. (MGNX)
  • OKYO Pharma Limited (OKYO)
  • Pliant Therapeutics, Inc. (PLRX)

Recent insider activity

  • CERRONE GABRIELE M — A-Award (15000 shares) on 2026-06-12
  • Shah Keeren Rameshchandra — trade (0 shares) on 2026-03-18
  • Shah Keeren Rameshchandra — trade (15625 shares) on 2024-05-06
  • Shah Keeren Rameshchandra — trade (46875 shares) on 2027-03-14
  • Shah Keeren Rameshchandra — trade (83333 shares) on 2027-03-13

Open Tiziana Life Sciences Ltd (TLSA) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.